Early [18F]florbetaben and [11C]PiB PET images are a surrogate biomarker of neuronal injury in Alzheimer’s disease

Purpose[18F]FDG is a commonly used neuronal injury biomarker for early and differential diagnosis of dementia. Typically, the blood supply to the brain is closely coupled to glucose consumption. Early uptake of the Aβ tracer [11C]PiB on PET images is mainly determined by cerebral blood flow and shows a high correlation with [18F]FDG uptake. Uptake data for 18F-labelled Aβ PET tracers are, however, scarce. We investigated the value of early PET images using the novel Aβ tracer [18F]FBB in the diagnosis of Alzhimers disease (AD).MethodsThis retrospective analysis included 22 patients with MCI or dementia who underwent dual time-point PET imaging with either [11C]PiB (11 patients) or [18F]FBB (11 patients) in routine clinical practice. Images were acquired 1 – 9 min after administration of both tracers and 40 – 70 min and 90 – 110 min after administration of [11C]PiB and [18F]FBB, respectively. The patients also underwent [18F]FDG brain PET imaging. PET data were analysed visually and semiquantitatively. Associations between early Aβ tracer uptake and dementia as well as brain atrophy were investigated.ResultsRegional visual scores of early Aβ tracer and [18F]FDG PET images were significantly correlated (Spearman’s ρ = 0.780, P < 0.001). Global brain visual analysis revealed identical results between early Aβ tracer and [18F]FDG PET images. In a VOI-based analysis, the early Aβ tracer data correlated significantly with the [18F]FDG data (r = 0.779, P < 0.001), but there were no differences between [18F]FBB and [11C]PiB. Cortical SUVRs in regions typically affected in AD on early Aβ tracer and [18F]FDG PET images were correlated with MMSE scores (ρ = 0.458, P = 0.032, and ρ = 0.456, P = 0.033, respectively). A voxel-wise group-based search for areas with relatively higher tracer uptake on early Aβ tracer PET images compared with [18F]FDG PET images revealed a small cluster in the midbrain/pons; no significant clusters were found for the opposite comparison.ConclusionEarly [18F]FBB and [11C]PiB PET brain images are similar to [18F]FDG PET images in AD patients, and these tracers could potentially be used as biomarkers in place of [18F]FDG. Thus, Aβ tracer PET imaging has the potential to provide biomarker information on AD pathology and neuronal injury. The potential of this approach for supporting the diagnosis of AD needs to be confirmed in prospective studies in larger cohorts.

[1]  Peter Herscovitch,et al.  Appropriate use criteria for amyloid PET: A report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association , 2013, Alzheimer's & Dementia.

[2]  Masanori Ichise,et al.  PET Quantification of 18F-Florbetaben Binding to β-Amyloid Deposits in Human Brains , 2013, The Journal of Nuclear Medicine.

[3]  Gunnar Antoni,et al.  Unidirectional Influx and Net Accumulation of PIB , 2008, The open neuroimaging journal.

[4]  M. Hüll,et al.  Dual-Biomarker Imaging of Regional Cerebral Amyloid Load and Neuronal Activity in Dementia with PET and 11C-Labeled Pittsburgh Compound B , 2011, The Journal of Nuclear Medicine.

[5]  H. Gertz,et al.  Individualized quantification of brain β-amyloid burden: results of a proof of mechanism phase 0 florbetaben PET trial in patients with Alzheimer’s disease and healthy controls , 2011, European Journal of Nuclear Medicine and Molecular Imaging.

[6]  Eveliina Arponen,et al.  Visual assessment of [11C]PIB PET in patients with cognitive impairment , 2010, European Journal of Nuclear Medicine and Molecular Imaging.

[7]  J. Morris,et al.  The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[8]  Nick C Fox,et al.  Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria , 2014, The Lancet Neurology.

[9]  Arno Villringer,et al.  Differential effects of global and cerebellar normalization on detection and differentiation of dementia in FDG-PET studies , 2010, NeuroImage.

[10]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease , 1984, Neurology.

[11]  C. Rowe,et al.  Comparison of 11C-PiB and 18F-florbetaben for Aβ imaging in ageing and Alzheimer’s disease , 2012, European Journal of Nuclear Medicine and Molecular Imaging.

[12]  Anton Forsberg,et al.  The use of PIB-PET as a dual pathological and functional biomarker in AD. , 2012, Biochimica et biophysica acta.

[13]  A. Drzezga,et al.  Current status and future role of brain PET/MRI in clinical and research settings , 2015, European Journal of Nuclear Medicine and Molecular Imaging.

[14]  Matthias L. Schroeter,et al.  Combined Imaging Markers Dissociate Alzheimer's Disease and Frontotemporal Lobar Degeneration – An ALE Meta-Analysis , 2011, Front. Ag. Neurosci..

[15]  John Seibyl,et al.  Cerebral amyloid-β PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study , 2011, The Lancet Neurology.

[16]  J. Seibyl,et al.  The role of positron emission tomography imaging in understanding Alzheimer’s disease , 2015, Expert review of neurotherapeutics.

[17]  I. Apostolova,et al.  Association between FDG uptake, CSF biomarkers and cognitive performance in patients with probable Alzheimer's disease , 2009 .

[18]  John Seibyl,et al.  Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer's disease: Phase 3 study , 2015, Alzheimer's & Dementia.

[19]  C. Jack,et al.  Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade , 2010, The Lancet Neurology.

[20]  S. Pappatà,et al.  Appropriate use criteria for amyloid PET imaging cannot replace guidelines: On behalf of the European Association of Nuclear Medicine , 2013, European Journal of Nuclear Medicine and Molecular Imaging.

[21]  P. Scheltens,et al.  Atrophy of medial temporal lobes on MRI in "probable" Alzheimer's disease and normal ageing: diagnostic value and neuropsychological correlates. , 1992, Journal of neurology, neurosurgery, and psychiatry.

[22]  S. DeKosky,et al.  Kinetic Modeling of Amyloid Binding in Humans using PET Imaging and Pittsburgh Compound-B , 2005, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[23]  D. Yves von Cramon,et al.  Neural networks in frontotemporal dementia—A meta-analysis , 2008, Neurobiology of Aging.

[24]  T. Yen,et al.  Correlation of early-phase 18F-florbetapir (AV-45/Amyvid) PET images to FDG images: preliminary studies , 2012, European Journal of Nuclear Medicine and Molecular Imaging.

[25]  H. Engler,et al.  Dynamic changes in PET amyloid and FDG imaging at different stages of Alzheimer's disease , 2012, Neurobiology of Aging.

[26]  Cindee M. Madison,et al.  Early 11C-PIB Frames and 18F-FDG PET Measures Are Comparable: A Study Validated in a Cohort of AD and FTLD Patients , 2011, The Journal of Nuclear Medicine.

[27]  Swen Hesse,et al.  Influence of scan duration on the accuracy of β-amyloid PET with florbetaben in patients with Alzheimer’s disease and healthy volunteers , 2012, European Journal of Nuclear Medicine and Molecular Imaging.

[28]  Matthias L. Schroeter,et al.  Neural correlates of Alzheimer's disease and mild cognitive impairment: A systematic and quantitative meta-analysis involving 1351 patients , 2009, NeuroImage.